Vaccine Safety Registry
Smallpox Vaccine Safety
Institutional safety information on Smallpox (JYNNEOS, ACAM2000) vaccines. Clinical safety data, side effects, biodefense protocols, and monitoring.
Written by
Dr. Simran Kohli, MBBS, MD (General Medicine), DM (Infectious Diseases)
View Clinical ProfileMedically reviewed by
Dr. Rohan Gupta, MBBS, MD (Dermatology, Venereology & Leprosy)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Smallpox is a high-consequence viral pathology induced by the Variola virus. Historically associated with high mortality rates and systemic morbidity, there is currently no specific therapeutic treatment beyond preventive immunization protocols.
Following global eradication in 1977, routine public immunization was terminated. Contemporary registry modules are maintained strictly for specialized cohorts within biodefense and orthopoxvirus research sectors.
Vaccine Formulations
Module specifics & formulations
Formulation Node
JYNNEOS
Preferred Protocol
- Live, non-replicating viral node.
- Dual protection: Smallpox and Mpox.
- Safer for immunocompromised cohorts.
- 2-dose titration (4-week interval).
Formulation Node
ACAM2000
Replicating Module
- Live, replicating viral vaccine.
- Single-dose administration.
- Requires bifurcated needle technique.
- Induces characteristic cutaneous reaction.
Clinical Triage
Eligibility & contraindications
Occupational High-Risk
- Orthopoxvirus laboratory personnel
- Smallpox clinical response units
- Active-duty military (at-risk zones)
Emergency Response
- Public health emergency responders
- Clinicians treating suspected cases
- Close contacts of confirmed nodes
Absolute & Relative Contraindications
- Severe clinical immunodeficiency
- Gestational status (Pregnancy)
- Chronic dermatological conditions such as eczema
Adverse Events
Reported reactions & surveillance
JYNNEOS Reactions
- Injection site pain / erythema
- Localized pruritus (Itching)
- Generalized myalgia / fatigue
ACAM2000 Profile
- Required cutaneous site reaction
- Localized lymphadenopathy
- Pyrexia (Fever)
- Generalized lethargy
Critical AE Vigilance (ACAM2000)
- Myocarditis / pericarditis
- Encephalitis (Brain inflammation)
- Inadvertent autoinoculation
- Severe cutaneous reactions
Surveillance Analytics
Post-market surveillance metrics
1972
U.S. Routine Termination
1977
Last Natural Case
2026
Biodefense Cycle
Institutional Surveillance
Contemporary smallpox immunization programs utilize JYNNEOS as the primary protocol due to its superior safety index. Risk-benefit triage remains the mandatory baseline for all biodefense vaccination decisions.
Editorial Governance
Clinical Reviewers & Authors
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Smallpox Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recommendations and Reports, 52(RR07):1-16
- 2WHO2024Smallpox and orthopoxviruses technical report
World Health Organization Advisory Committee on Variola Virus Research
- 3FDA2024ACAM2000 and JYNNEOS Prescribing Information & Post-Licensure Surveillance
U.S. Food and Drug Administration CBER Biologics Summary
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Simran Kohli and clinically reviewed by Dr. Rohan Gupta, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.